modelN03AX23
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Brivaracetam | |
| ATC code: | N03AX23 | route: | oral |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 3.46 | L/h |
| other parameters in model implementation | ||
Brivaracetam is an anticonvulsant medication used as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy. It is a high-affinity ligand for synaptic vesicle protein 2A (SV2A) and is approved for use in several countries, including the US and EU.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult subjects (both sexes, ages 18-65) after oral administration.
References
Klein, P, & Bourikas, D (2024). Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. Advances in therapy 41(7) 2682–2699. DOI:10.1007/s12325-024-02876-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/38811492
Schoemaker, R, et al., & Stockis, A (2017). Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. European journal of clinical pharmacology 73(6) 727–733. DOI:10.1007/s00228-017-2230-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28280887
Stockis, A, et al., & Krauwinkel, W (2023). Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants. Clinical pharmacology in drug development 12(11) 1121–1127. DOI:10.1002/cpdd.1264 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37212183
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)